Leonabio, INC. (LONA) — SEC Filings

Overview

Leonabio, INC. (LONA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 2, 2026: LeonaBio, Inc. filed an EFFECT form on April 2, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-001046, relates to Act 33 and File No. 333-292829. The company's business address is 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011.

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 2 bearish, 25 neutral, 2 mixed. The dominant filing sentiment for Leonabio, INC. is neutral.

Filing Type Overview

Leonabio, INC. (LONA) has filed 2 EFFECT, 1 8-K/A, 6 10-Q, 11 8-K, 2 DEF 14A, 2 10-K, 1 SC 13G/A, 2 SC 13G, 1 SC 13D/A, 1 10-Q/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

• LeonaBio, Inc. Registration Statement Declared Effective — EFFECT · Apr 2, 2026 Risk: low
  LeonaBio, Inc. filed an EFFECT form on April 2, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-
• EFFECT Filing — EFFECT · Apr 2, 2026
• 8-K/A Filing — 8-K/A · Dec 18, 2025
• Athira Pharma Slashes Losses, Eyes Future Funding Amid Cash Burn — 10-Q · Nov 6, 2025 Risk: high
  Athira Pharma, Inc. (ATHA) reported a significant reduction in net loss and operating expenses for the nine months ended September 30, 2025, compared to the sam
• Athira Pharma Files 8-K Report — 8-K · Oct 3, 2025 Risk: medium
  On October 2, 2025, Athira Pharma, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regardin
• Athira Pharma Files 8-K on Security Holder Rights — 8-K · Sep 11, 2025 Risk: medium
  Athira Pharma, Inc. filed an 8-K on September 10, 2025, reporting material modifications to the rights of security holders and amendments to its articles of inc
• Athira Pharma Narrows Q2 Loss Amid R&D Streamlining — 10-Q · Aug 7, 2025 Risk: high
  Athira Pharma, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net loss for
• Athira Pharma Files 8-K on Shareholder Votes — 8-K · Jun 2, 2025 Risk: low
  Athira Pharma, Inc. filed an 8-K on May 29, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific details
• Athira Pharma Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: medium
  Athira Pharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position and operational highlights, including detai
• Athira Pharma Faces Delisting Concerns — 8-K · Apr 16, 2025 Risk: high
  Athira Pharma, Inc. has filed an 8-K report on April 15, 2025, indicating a notice of delisting or failure to satisfy a continued listing rule or standard. The
• Athira Pharma Files Definitive Proxy Statement — DEF 14A · Apr 14, 2025 Risk: low
  Athira Pharma, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 14, 2025, for its annual meeting on May 29, 2025. The company, formerly known as M3 Bi
• 10-K Filing — 10-K · Feb 27, 2025
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 7, 2024
• Athira Pharma Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Athira Pharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial position and operational highlights. Key financi
• Perceptive Advisors Amends Athira Pharma Stake — SC 13D/A · Oct 31, 2024 Risk: medium
  Perceptive Advisors LLC, through its affiliated entities, has amended its Schedule 13D filing regarding Athira Pharma, Inc. The filing, dated October 31, 2024,
• Athira Pharma Faces Nasdaq Delisting Warning — 8-K · Oct 18, 2024 Risk: high
  Athira Pharma, Inc. announced on October 16, 2024, that it received a notice from The Nasdaq Stock Market indicating a failure to meet the minimum bid price req
• Athira Pharma Announces Board, Executive Changes & Compensation — 8-K · Oct 7, 2024 Risk: medium
  Athira Pharma, Inc. announced on October 1, 2024, changes in its board of directors and executive compensation. Dr. Hans-Ulrich Siehl has been appointed as a ne
• Athira Pharma CMO Departs, Interim Appointed — 8-K · Sep 17, 2024 Risk: medium
  Athira Pharma, Inc. announced on September 15, 2024, the departure of its Chief Medical Officer, Dr. T. David Smith, and the appointment of Dr. Hans-Ulrich Demu
• Athira Pharma Files 8-K Report — 8-K · Sep 3, 2024 Risk: low
  On September 3, 2024, Athira Pharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements a
• Athira Pharma Files 10-Q/A Amendment — 10-Q/A · Aug 9, 2024 Risk: medium
  Athira Pharma, Inc. filed an amendment (10-Q/A) on August 9, 2024, for the quarterly period ended June 30, 2024. The filing pertains to their operations as a bi
• Athira Pharma Files Q2 2024 10-Q — 10-Q · Aug 1, 2024 Risk: medium
  Athira Pharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the six months ended June 30,
• Athira Pharma Files 8-K on Shareholder Votes & Financials — 8-K · May 29, 2024 Risk: low
  Athira Pharma, Inc. filed an 8-K on May 23, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing details the
• Athira Pharma Files 8-K — 8-K · May 17, 2024 Risk: low
  Athira Pharma, Inc. filed an 8-K on May 17, 2024, reporting an event that occurred on May 3, 2024. The filing pertains to financial statements and exhibits, ind
• Athira Pharma Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: low
  Athira Pharma, Inc. (LONA) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Athira Pharma, Inc. filed a 10-Q report for the period ending March 31,
• Athira Pharma Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 9, 2024 Risk: low
  Athira Pharma, Inc. (LONA) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. Athira Pharma, Inc. will hold its 2024 Annual Meeting of Stockholder
• Athira Pharma Files 2023 Annual Report on Form 10-K — 10-K · Feb 22, 2024 Risk: medium
  Athira Pharma, Inc. (LONA) filed a Annual Report (10-K) with the SEC on February 22, 2024. Athira Pharma, Inc. filed its 10-K report for the fiscal year ending
• SC 13G Filing — SC 13G · Feb 14, 2024
• Athira Pharma 8-K: Operations, Officer Changes Reported Jan 4 — 8-K · Jan 8, 2024
  Athira Pharma, Inc. filed an 8-K on January 8, 2024, reporting events that occurred on January 4, 2024. This filing indicates that the company is updating its p

Risk Profile

Risk Assessment: Of LONA's 22 recent filings, 4 were flagged as high-risk, 10 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Leonabio, INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: N/A
• Net Income: -$22.7M
• EPS: N/A
• Debt-to-Equity: 0.12
• Cash Position: $20.9M
• Operating Margin: N/A
• Total Assets: $30.0M
• Total Debt: $3.2M

Key Executives

• Wang VAthiraPharmaIncMember
• Joseph Edelman
• Dr. Hans-Ulrich Siehl
• Mark L. Gordon
• R. Michael Shannon
• Dr. T. David Smith
• Dr. Hans-Ulrich Demuth
• Mark J. Litton, Ph.D.

Industry Context

The biotechnology sector is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies like Athira Pharma focus on developing novel therapies for complex diseases, often facing intense competition from both established pharmaceutical giants and other emerging biotechs. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.

Top Tags

financials (5) · sec-filing (4) · 10-Q (4) · Biotechnology (3) · biotech (3) · Athira Pharma (3) · Cash Burn (2) · 8-K (2) · corporate-governance (2) · amendment (2)

Key Numbers

• Net Loss: $22.7M — Decreased by 72.2% from $81.9M in 2024 for the nine months ended September 30, 2025.
• Research and Development Expenses: $10.8M — Decreased by 82.4% from $61.3M in 2024 for the nine months ended September 30, 2025.
• General and Administrative Expenses: $12.9M — Decreased by 35.1% from $19.9M in 2024 for the nine months ended September 30, 2025.
• Cash and Cash Equivalents: $20.9M — As of September 30, 2025, down from $48.4M at December 31, 2024.
• Total Cash, Cash Equivalents and Investments: $25.2M — As of September 30, 2025, estimated to fund operations for at least the next 12 months.
• ATM Equity Offering Facility: $75.0M — Available for future capital raises, no securities sold yet.
• Reverse Stock Split Ratio: 1-for-10 — Effected on September 17, 2025, to maintain Nasdaq listing.
• Shares Outstanding: 3,943,887 — As of September 30, 2025, post-reverse stock split.
• SEC File Number: 001-39503 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 45-3368487 — Company's tax identification number.
• Net Loss (Q2 2025): $25.3M — Decreased from $27.1M in Q2 2024, indicating a narrower loss.
• Net Loss (YTD 2025): $50.1M — Decreased from $53.8M in YTD 2024, showing improved financial efficiency.
• R&D Expenses (Q2 2025): $18.9M — Reduced from $20.9M in Q2 2024, primarily due to lower clinical trial costs.
• G&A Expenses (Q2 2025): $6.4M — Slightly increased from $6.2M in Q2 2024.
• Cash & Equivalents (June 30, 2025): $150.2M — Provides operational runway into 2026, crucial for a clinical-stage company.

Related Companies

ATHA

Frequently Asked Questions